2019 ASCCP 基于风险的管理共识指南：更新至 2023 年。

IF 2.4 4区医学 Q2 OBSTETRICS & GYNECOLOGY Journal of Lower Genital Tract Disease Pub Date : 2023-12-20 DOI:10.1097/lgt.0000000000000788

Rebecca B Perkins, Richard S Guido, Philip E Castle, David Chelmow, Mark H Einstein, Francisco Garcia, Warner K Huh, Jane J Kim, Anna-Barbara Moscicki, Ritu Nayar, Mona Saraiya, George F Sawaya, Nicolas Wentzensen, Mark Schiffman

{"title":"2019 ASCCP 基于风险的管理共识指南：更新至 2023 年。","authors":"Rebecca B Perkins, Richard S Guido, Philip E Castle, David Chelmow, Mark H Einstein, Francisco Garcia, Warner K Huh, Jane J Kim, Anna-Barbara Moscicki, Ritu Nayar, Mona Saraiya, George F Sawaya, Nicolas Wentzensen, Mark Schiffman","doi":"10.1097/lgt.0000000000000788","DOIUrl":null,"url":null,"abstract":"This Research Letter summarizes all updates to the 2019 Guidelines through September 2023, including: endorsement of the 2021 Opportunistic Infections guidelines for HIV+ or immunosuppressed patients; clarification of use of human papillomavirus testing alone for patients undergoing observation for cervical intraepithelial neoplasia 2; revision of unsatisfactory cytology management; clarification that 2012 guidelines should be followed for patients aged 25 years and older screened with cytology only; management of patients for whom colposcopy was recommended but not completed; clarification that after treatment for cervical intraepithelial neoplasia 2+, 3 negative human papillomavirus tests or cotests at 6, 18, and 30 months are recommended before the patient can return to a 3-year testing interval; and clarification of postcolposcopy management of minimally abnormal results.","PeriodicalId":50160,"journal":{"name":"Journal of Lower Genital Tract Disease","volume":"10 1","pages":""},"PeriodicalIF":2.4000,"publicationDate":"2023-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"2019 ASCCP Risk-Based Management Consensus Guidelines: Updates Through 2023.\",\"authors\":\"Rebecca B Perkins, Richard S Guido, Philip E Castle, David Chelmow, Mark H Einstein, Francisco Garcia, Warner K Huh, Jane J Kim, Anna-Barbara Moscicki, Ritu Nayar, Mona Saraiya, George F Sawaya, Nicolas Wentzensen, Mark Schiffman\",\"doi\":\"10.1097/lgt.0000000000000788\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"This Research Letter summarizes all updates to the 2019 Guidelines through September 2023, including: endorsement of the 2021 Opportunistic Infections guidelines for HIV+ or immunosuppressed patients; clarification of use of human papillomavirus testing alone for patients undergoing observation for cervical intraepithelial neoplasia 2; revision of unsatisfactory cytology management; clarification that 2012 guidelines should be followed for patients aged 25 years and older screened with cytology only; management of patients for whom colposcopy was recommended but not completed; clarification that after treatment for cervical intraepithelial neoplasia 2+, 3 negative human papillomavirus tests or cotests at 6, 18, and 30 months are recommended before the patient can return to a 3-year testing interval; and clarification of postcolposcopy management of minimally abnormal results.\",\"PeriodicalId\":50160,\"journal\":{\"name\":\"Journal of Lower Genital Tract Disease\",\"volume\":\"10 1\",\"pages\":\"\"},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2023-12-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Lower Genital Tract Disease\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/lgt.0000000000000788\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"OBSTETRICS & GYNECOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Lower Genital Tract Disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/lgt.0000000000000788","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

本研究报告总结了 2019 年指南至 2023 年 9 月的所有更新内容，包括认可针对 HIV+ 或免疫抑制患者的 2021 年机会性感染指南；明确对接受宫颈上皮内瘤变 2 观察的患者仅使用人类乳头瘤病毒检测；修订不满意细胞学管理；明确 25 岁及以上仅接受细胞学筛查的患者应遵循 2012 年指南；对建议进行阴道镜检查但未完成检查的患者的管理；明确宫颈上皮内瘤变 2+ 治疗后，建议在 6、18 和 30 个月时进行 3 次阴性人类乳头瘤病毒检测或联合检测，然后才能恢复到 3 年检测间隔；明确阴道镜检查后对轻微异常结果的管理。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

2019 ASCCP Risk-Based Management Consensus Guidelines: Updates Through 2023.

This Research Letter summarizes all updates to the 2019 Guidelines through September 2023, including: endorsement of the 2021 Opportunistic Infections guidelines for HIV+ or immunosuppressed patients; clarification of use of human papillomavirus testing alone for patients undergoing observation for cervical intraepithelial neoplasia 2; revision of unsatisfactory cytology management; clarification that 2012 guidelines should be followed for patients aged 25 years and older screened with cytology only; management of patients for whom colposcopy was recommended but not completed; clarification that after treatment for cervical intraepithelial neoplasia 2+, 3 negative human papillomavirus tests or cotests at 6, 18, and 30 months are recommended before the patient can return to a 3-year testing interval; and clarification of postcolposcopy management of minimally abnormal results.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of Lower Genital Tract Disease OBSTETRICS & GYNECOLOGY-

CiteScore

6.80

自引率

8.10%

发文量

158

审稿时长

6-12 weeks

期刊介绍： The Journal of Lower Genital Tract Disease is the source for the latest science about benign and malignant conditions of the cervix, vagina, vulva, and anus. The Journal publishes peer-reviewed original research original research that addresses prevalence, causes, mechanisms, diagnosis, course, treatment, and prevention of lower genital tract disease. We publish clinical guidelines, position papers, cost-effectiveness analyses, narrative reviews, and systematic reviews, including meta-analyses. We also publish papers about research and reporting methods, opinions about controversial medical issues. Of particular note, we encourage material in any of the above mentioned categories that is related to improving patient care, avoiding medical errors, and comparative effectiveness research. We encourage publication of evidence-based guidelines, diagnostic and therapeutic algorithms, and decision aids. Original research and reviews may be sub-classified according to topic: cervix and HPV, vulva and vagina, perianal and anal, basic science, and education and learning. The scope and readership of the journal extend to several disciplines: gynecology, internal medicine, family practice, dermatology, physical therapy, pathology, sociology, psychology, anthropology, sex therapy, and pharmacology. The Journal of Lower Genital Tract Disease highlights needs for future research, and enhances health care. The Journal of Lower Genital Tract Disease is the official journal of the American Society for Colposcopy and Cervical Pathology, the International Society for the Study of Vulvovaginal Disease, and the International Federation of Cervical Pathology and Colposcopy, and sponsored by the Australian Society for Colposcopy and Cervical Pathology and the Society of Canadian Colposcopists.